Pomerantz Law Firm Establishes Investigation into Soleno Therapeutics Amid Allegations of Misconduct

Investigative Alert: Pomerantz Law Firm and Soleno Therapeutics

Pomerantz LLP has initiated an investigation focused on behalf of investors associated with Soleno Therapeutics, Inc. (NASDAQ: SLNO). This inquiry is essential as it relates to allegations of securities fraud and unlawful business practices potentially involving the company's executives. Recently, a significant report emerged from Scorpion Capital, raising serious concerns about Soleno's primary product, Vykat XR, particularly questioning its pricing and safety for children.

On August 15, 2025, Scorpion released findings that labeled Vykat XR as overpriced and possibly unsafe, which led to a concerning drop in Soleno's stock value. On that day, the stock plummeted by $5.73, equating to a 7.41% decrease, ultimately closing at $71.63 per share. This sharp decline has reiterated the need for investor vigilance, prompting Pomerantz’s involvement.

Pomerantz LLP, renowned for its expertise in corporate, securities, and antitrust class litigation, continues its long-standing tradition of advocating for the rights of investors and class members. Established over 85 years ago by Abraham L. Pomerantz, the firm has a legacy of recovering substantial damages for victims of corporate misconduct and securities fraud.

The firm's primary goal during this investigation is to gauge whether Soleno Therapeutics and its leadership have strayed from lawful practices, thus violating their ethical obligations to shareholders. Interested investors are encouraged to reach out for more information on how to join any potential class action claims.

If you have been affected by the recent decline in Soleno’s stock value and wish to explore your legal options, the firm has advised contacting Danielle Peyton at [email protected] or by phone at 646-581-9980, ext. 7980.

Pomerantz's significant presence in major cities including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv positions it uniquely for handling such investigations

As the investigation unfolds, it will undoubtedly shed light on the company’s practices and the legitimacy of its product claims. Keeping in mind the gravity of the allegations, both investors and analysts alike are watching carefully as Soleno Therapeutics navigates this turbulent period. This situation emphasizes the critical importance of transparency and adherence to ethical standards in corporate governance.

Moreover, it serves as a reminder to investors regarding the risks associated with investments in biotech companies, where product promises must be met with accountability. Investors are urged to remain informed and proactive in tracking any developments regarding Soleno Therapeutics in the coming days, which could significantly impact the market dynamics for the company and its shareholders. Stay tuned for updates as Pomerantz Law Firm works diligently to secure the rights of the investors involved.